ADX-097 is under clinical development by Q32 Bio Operations and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADX-097’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ADX-097 overview

ADX-097 is under development for the treatment of ANCA Vasculitis, severe inflammatory diseases, membranoproliferative glomerulonephritis (mesangiocapillary glomerulonephritis) C3G, IgA nephropathy (Berger's disease) and lupus nephritis. The drug candidate is a tissue-targeted inhibitor of complement activation, humanized anti-C3d monoclonal antibody linked to two moieties of the first five consensus repeats of the complement negative regulatory protein human factor H (fH1-5), designed to target complement inhibition. It is administered through subcutaneous route.

Q32 Bio Operations overview

Q32 Bio Operations, formerly Q32 Bio Inc (Q32 Bio), is a biopharmaceutical manufacturing company. It is headquartered in Waltham, Massachusetts, the US.

For a complete picture of ADX-097’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.